May 28, 2009 by Brian Orelli, PhDMonsanto Plowed DownLow end of guidance is better than lowered guidance, I guess.
May 28, 2009 by Brian Orelli, PhDWhen All Else FailsSave the customer money so they can give it to you.
May 28, 2009 by Brian Orelli, PhDBoston Scientific Back in an Atomic WayCan its tiny stent save the day?
May 28, 2009 by Brian Orelli, PhDMake Money, Fight Disease: The ASCO PreviewThe big cancer meeting is upon us.
May 27, 2009 by Brian Orelli, PhDIt's Approved! Now Back to WorkBristol-Myers breathes a sigh of relief.
May 27, 2009 by Brian Orelli, PhDA Wrinkle in the Botox PlanThe FDA turns down a label expansion, but it wasn't all bad news.
May 27, 2009 by Brian Orelli, PhDMeet the People Who'll Rule Your Investment LifeIf you're a drug company investor, that is.
May 26, 2009 by Brian Orelli, PhDWill the FDA Approve These Drugs?Plenty of PDUFA dates are right around the corner.
May 26, 2009 by Brian Orelli, PhDBuy Now! It Might Get Bought!Investing on acquisition hope? You might as well go to Vegas.
May 26, 2009 by Brian Orelli, PhDWhen Higher Costs Are a Good ThingSteeper PDUFA fees for drugmakers may speed the FDA's decisions.
May 22, 2009 by Brian Orelli, PhDJ&J and Cougar: Meow or Roar?Buying the unproven, but the risk is a small fraction of the company.
May 22, 2009 by Brian Orelli, PhDNovartis Breathes EasierA triple-triple -- three positive phase 3 trials.
May 21, 2009 by Brian Orelli, PhDNot So Fast, Schering ... er, Merck ... er, Whoever You AreTo arbitration you go.
May 21, 2009 by Brian Orelli, PhDIf You Can't Beat 'Em, Join 'Em: Pharma Goes GenericPotentially a good move, but they've got to do it right.
May 20, 2009 by Brian Orelli, PhDJoining to Treat, and Beat, DiabetesMedtronic and Eli Lilly become partners.
May 20, 2009 by Brian Orelli, PhDClinical Trial Positive, Stock Not So MuchIsis and Genzyme hit a homer, but they'll need another big play to win the game.
May 19, 2009 by Brian Orelli, PhDMedtronic Gets Whacked, Seeks Recovery DeviceMedtronic gets hammered on lackluster guidance.
